OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!
If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.
Requested Article:
Outcome-Based Payment Schemes: What Outcomes Do Patients with Cancer Value?
Paula Lorgelly, Jack Pollard, Patricia Cubí‐Mollá, et al.
Patient (2020) Vol. 13, Iss. 5, pp. 599-610
Open Access | Times Cited: 16
Paula Lorgelly, Jack Pollard, Patricia Cubí‐Mollá, et al.
Patient (2020) Vol. 13, Iss. 5, pp. 599-610
Open Access | Times Cited: 16
Showing 16 citing articles:
Prostate Cancer Vaccines: Progress, Challenges, and Future Directions
Stefanus Vicky Bernhard Elisa Runtunuwu, Trina Ekawati Tallei, Grace L. A. Turalaki
Heca Journal of Applied Sciences (2025) Vol. 3, Iss. 1, pp. 30-55
Closed Access
Stefanus Vicky Bernhard Elisa Runtunuwu, Trina Ekawati Tallei, Grace L. A. Turalaki
Heca Journal of Applied Sciences (2025) Vol. 3, Iss. 1, pp. 30-55
Closed Access
The Challenges of Outcomes-Based Contract Implementation for Medicines in Europe
N Böhm, Sarah Bermingham, Frank Grimsey Jones, et al.
PharmacoEconomics (2021) Vol. 40, Iss. 1, pp. 13-29
Open Access | Times Cited: 27
N Böhm, Sarah Bermingham, Frank Grimsey Jones, et al.
PharmacoEconomics (2021) Vol. 40, Iss. 1, pp. 13-29
Open Access | Times Cited: 27
Post‐Market Evidence for Cancer Medicines in Regulatory and Clinical Decision‐Making: A Scoping Review
Eliza J. McEwin, Ashleigh Hooimeyer, Barbara Mintzes
Pharmacoepidemiology and Drug Safety (2025) Vol. 34, Iss. 1
Closed Access
Eliza J. McEwin, Ashleigh Hooimeyer, Barbara Mintzes
Pharmacoepidemiology and Drug Safety (2025) Vol. 34, Iss. 1
Closed Access
Cancer treatments touch a wide range of values that count for patients and other stakeholders: What are the implications for decision‐making?
Cilla E.J. Vrinzen, Haiko J. Bloemendal, Esra Stuart, et al.
Cancer Medicine (2022) Vol. 12, Iss. 5, pp. 6105-6116
Open Access | Times Cited: 6
Cilla E.J. Vrinzen, Haiko J. Bloemendal, Esra Stuart, et al.
Cancer Medicine (2022) Vol. 12, Iss. 5, pp. 6105-6116
Open Access | Times Cited: 6
Prioritizing Outcome Measures for Value-Based Healthcare: Physicians’ Perspectives in Saudi Arabia
Rawia Abdalla, Milena Pavlova, Wim Groot
Value in Health Regional Issues (2023) Vol. 37, pp. 62-70
Open Access | Times Cited: 3
Rawia Abdalla, Milena Pavlova, Wim Groot
Value in Health Regional Issues (2023) Vol. 37, pp. 62-70
Open Access | Times Cited: 3
Patient and Public Involvement Refines the Design of ProtOeus: A Proposed Phase II Trial of Proton Beam Therapy in Oesophageal Cancer
O. Nicholas, Olivia Joseph, Annie Keane, et al.
Patient (2020) Vol. 14, Iss. 5, pp. 545-553
Open Access | Times Cited: 6
O. Nicholas, Olivia Joseph, Annie Keane, et al.
Patient (2020) Vol. 14, Iss. 5, pp. 545-553
Open Access | Times Cited: 6
Defining ‘therapeutic value’ of medicines: a scoping review
Camille E G Glaus, Andrina Kloeti, Kerstin Noëlle Vokinger
BMJ Open (2023) Vol. 13, Iss. 12, pp. e078134-e078134
Open Access | Times Cited: 2
Camille E G Glaus, Andrina Kloeti, Kerstin Noëlle Vokinger
BMJ Open (2023) Vol. 13, Iss. 12, pp. e078134-e078134
Open Access | Times Cited: 2
Cost-Utility of the CDK 4/6 Inhibitors for Postmenopausal Women With Luminal Advanced Breast Cancer in Brazil
Luana Schroeder Damico Nascimento Macedo, Aline Silveira Silva, Ana Cláudia Wekmuller França, et al.
Value in Health Regional Issues (2022) Vol. 31, pp. 47-52
Closed Access | Times Cited: 3
Luana Schroeder Damico Nascimento Macedo, Aline Silveira Silva, Ana Cláudia Wekmuller França, et al.
Value in Health Regional Issues (2022) Vol. 31, pp. 47-52
Closed Access | Times Cited: 3
Brazilian breast cancer patient-reported outcomes: What really matters for these women
Aline Silveira Silva, Ana Cláudia Wekmuller França, Matheus Piccin Padilla, et al.
Frontiers in Medical Technology (2022) Vol. 4
Open Access | Times Cited: 3
Aline Silveira Silva, Ana Cláudia Wekmuller França, Matheus Piccin Padilla, et al.
Frontiers in Medical Technology (2022) Vol. 4
Open Access | Times Cited: 3
Reporting reimbursement price decisions for onco-hematology drugs in Spain
David Elvira, Ferrán Torres, Roser Vives, et al.
Frontiers in Public Health (2023) Vol. 11
Open Access | Times Cited: 1
David Elvira, Ferrán Torres, Roser Vives, et al.
Frontiers in Public Health (2023) Vol. 11
Open Access | Times Cited: 1
Exploring the Important Determinants Shaping Treatment Preferences: Qualitative Insights into Breast Cancer Patient Experiences and Perspectives in New Zealand
Hui Yee Yeo, Jacqueline Hui Yi Wong, Suz Jack Chan, et al.
Patient Preference and Adherence (2023) Vol. Volume 17, pp. 3525-3537
Open Access | Times Cited: 1
Hui Yee Yeo, Jacqueline Hui Yi Wong, Suz Jack Chan, et al.
Patient Preference and Adherence (2023) Vol. Volume 17, pp. 3525-3537
Open Access | Times Cited: 1
Pay-for-performance schemes: 10 years’ experience in a comprehensive cancer center
Ana Clopés Estela, Francesc Soler Rotllant, J. R. Germá Lluch, et al.
Medicina Clínica (English Edition) (2022) Vol. 158, Iss. 10, pp. 488-492
Closed Access | Times Cited: 2
Ana Clopés Estela, Francesc Soler Rotllant, J. R. Germá Lluch, et al.
Medicina Clínica (English Edition) (2022) Vol. 158, Iss. 10, pp. 488-492
Closed Access | Times Cited: 2
Esquemas de pago basados en resultados de medicamentos: experiencia de 10 años en un centro monográfico de cáncer
Ana Clopés Estela, Francesc Soler Rotllant, J. R. Germá Lluch, et al.
Medicina Clínica (2022) Vol. 158, Iss. 10, pp. 488-492
Closed Access | Times Cited: 1
Ana Clopés Estela, Francesc Soler Rotllant, J. R. Germá Lluch, et al.
Medicina Clínica (2022) Vol. 158, Iss. 10, pp. 488-492
Closed Access | Times Cited: 1
Challenges and Opportunities to Access Innovation in Latin America: The Case of Combination Therapies for Multiple Myeloma
Cristina Gutierrez Delgado, Virginia Abello, Martha Alvarado, et al.
RAS Oncology & Therapy (2022) Vol. 3, Iss. 1
Open Access | Times Cited: 1
Cristina Gutierrez Delgado, Virginia Abello, Martha Alvarado, et al.
RAS Oncology & Therapy (2022) Vol. 3, Iss. 1
Open Access | Times Cited: 1
Cost Effectiveness of Molecular Diagnostic Testing Algorithms for the Treatment Selection of Frontline Ibrutinib for Patients with Chronic Lymphocytic Leukemia in Australia
Martin Vu, Koen Degeling, Ella R. Thompson, et al.
Applied Health Economics and Health Policy (2023) Vol. 22, Iss. 1, pp. 107-122
Open Access
Martin Vu, Koen Degeling, Ella R. Thompson, et al.
Applied Health Economics and Health Policy (2023) Vol. 22, Iss. 1, pp. 107-122
Open Access
